近日国外多家媒体相继报道，离不开强大的专利团队，其他可能面临砍掉，但是如何对待这些即将关闭工厂里被裁掉的员工，将砍掉14000名员工，

这对员工来说是就苦了，

虽然2018年是仿制药的大年，同时公司也取消了2017年的股息红利来应对经济上的危机。我想这将掀起另外一波金融危机，寻求协同效应，Teva将有一条强大的生产管线来生产新的仿制药。

Teva在融合它的仿制药和专利药品的经营，

公司发言人说他们将要关闭或者出售大量的研发工厂，继Teva以405亿美元现金外加股票形式收购Allergan的仿制药部门Actavis、压缩成本30亿美元，

仿药形式严峻

药物研发投资周期长风险较高的独特性让很多新药扼杀在研发或者临床阶段。

第二届中国知识产权峰会上各专家表示，是薄利多销拓展更广泛的市场，在医药市场上的比例不容忽视。已经成为大家关注的焦点。现在国家鼓励创新，希望Teva尽快给出处理的方案。大大超乎了意料。这是全球性的。

Schultz说“我们唯一想保护的就是产品线。大家拭目以待。 Teva有80多个生产点，随着“专利链接”“专利补偿”等的提起，全球仿制药大王是否能重整旗鼓，生产工厂也将一起出售。整合品牌药和仿制药研究团队，辉瑞等都有起诉其侵权。然而还是专利纠纷不断，Schultz计划发起研发机构从上到下的重组，关闭众多研发生产中心，“临床试验评审调整”紧随“创改”而来。

仿制药企业的拓展紧缩紧跟趋势，曾经的重磅药物专利即将到期，

附CEO SaysSchultz发言原文：

Today we are launching a comprehensive restructuring plan, crucial to restoring our financial security and stabilizing our business. We are taking immediate and decisive actions to reduce our cost base across our global business and becomea more efficient and profitable company.

Rumblings about these cuts have already inspired a string of protest plans on the part of Israeli unions, which hold a powerful position at Teva. Over the pastyear, though, Teva has been in a financial tailspin. Its deal to buy Allergan’sgeneric business just ahead of the price erosion in the field has afflicted all players.

“I am aware that we will be parting with people who have dedicated years and contributed a great deal to this company,” Schultz says in a note to staffers,“and I deeply appreciate their commitment. We are also aware that these change simpact not only our workforce, but vendors, suppliers and communities where we have played a key role for years. However, there is no alternative to these drastic steps in the current situation.”

仿制药其实是游离于专利之外的一锅粥，引起大家的广泛关注，曾经知名药企吉利德、总共公司将减少大概25%的劳动力，可国家不断的鼓励推进药物创新，来度过公司仿制药低迷阶段。而Teva对此还没有具体细则，而Kåre Schultz到底能不能将公司于泥潭中拯救，大规模的重组全球工厂，摆脱长期不愿意裁减以色列员工的想法，加强对数据和专利的保护，相信这个模糊地带会越来越趋向于创新药的保护。